The deal is the result of restructuring a collaboration, which began in 2020 to develop mRNA-based vaccines for infectious diseases, into a new licensing agreement, GSK added. As a result of the collaboration, the two companies have vaccine candidates for seasonal influenza and COVID-19 in phase II clinical development and avian influenza in phase I clinical development.
Breaking
An apocalyptic wall of smoke, flames, and howling winds sent a Southern California homeowner fleeing for her life....
Pope Pius XI taught that 'When once men recognize, both in private and in public life, that Christ is King, society will at last receive the great blessings of real liberty, well-ordered discipline, p...
Elon Musk's SpaceX is moving ahead with plans to go public in what some expect will be the biggest IPO ever....
loading...